Terapia de mantenimiento con inhibidores de PARP en cáncer de ovario: Un nuevo concepto para aumentar la supervivencia en la enfermedad recurrente

26 / 40

Olaparib
(SOLO-2)
Niraparib
(NOVA)
Rucaparib
(ARIEL 3)
Discontinuation 11% 14.7% 13.4%
Dose reduction 25% 66.5% 54.6%
Related SAE 17.9% 16.9% -
Nausea/vomiting 2.6% 3% 7.8%
Fatigue 4.1% 8% 6.7%
Anemia 19.5% 25 % 18.8%
Thrombocytopenia 1% 33 % 5.1%
Neutropenia 5.1% 19% 6.7%
Hypertension - 8.2% -
GOT/GPT - - 10.5%
MDS 4 (2.1%) 5 (1.4%) 3 (0.8%)
1. Pujade et al. Lancet Oncol 2017; 18: 1274–84 2. Mirza et al. N Eng J Med 2016;375(22):2154-2164.; 3. Coleman et al. Lancet 2017; 390: 1949–61
Safety profile (Toxicity Grade > 3 )